PubMed Health⌕ Search

Biomedical subjects

H Schneble

Publications and source records attributed to H Schneble.

At least 19 recordsLinked to original sources
PubMed1998

[Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin].

Valproate is a frequently used antiepileptic drug. It is associated with rare but serious adverse effects like liver failure. The first symptom is impairment of the patient's well being. Isolated changes of standard laboratory liver parameters are not reliable early indicators. Thus, according to the knowledge of today, prophylactic blood screening cannot predict complications. On the contrary, clinical symptoms are the most relevant indicators of impending complications, eventually supported by laboratory findings. An abrupt withdrawal of valproate and administering carnitin in parallel can interrupt the otherwise fatal course of the complication and induce a subsequent recovery. At a Consensus Conference the current knowledge about early detection and therapy of the valproate-induced serious hepatotoxicity was discussed. The results regarding recommended laboratory screening, as well as diagnostic and therapeutic strategies are reported.

Adolescent↗
PubMed1995

[Old wine in new bottles: the "promille-killer" Party Plus].

We report about the allegedly new sobering up preparation called PARTY-PLUS, the ingredients of which resemble very much those of the inefficient "drink with a sobering up effect NEUKAMM-lemonade". In a drinking experiment Verum vs. Placebo (a light mineral water) the inefficiency of the alcohol elimination kinetics is proved once again, especially with regards to the extent of success suggested in advertising. Official bodies of administration of justice and legislation are called upon to oppose such doings of manufacturers and distributors more firmly. This is necessary because expected side effects and health hazards due to the high fructose contents are deliberately played down or concealed altogether.

Adult↗
PubMed1994

pNAT and CYP2D6 gene polymorphism in epileptic patients.

Certain anticonvulsant drugs require N-acetylation as a major route of metabolic clearance. Single point mutations of the polymorphic N-acetyltransferase gene (pNAT) are the primary cause for impaired drug acetylation. Pharmacokinetic parameters are altered in slow acetylator phenotypes and this may compromise drug safety. Genetic analysis of allelic frequencies of individual pNAT genotypes point to significant increases in carriers of the S1/wt and S3/wt (P < 0.05) allele and a significant reduction in carriers of the S2/S2 (P < 0.01) allele, when control and epileptic patients are compared. Furthermore, the presumed link between the cytochrome P450 CYP2D6 polymorphism and the pathogenesis of Parkinson's disease led us to investigate, whether a similar relationship can be expected for other CNS disorders. Our findings indicate that poor metabolizers are more frequent (P < 0.05) amongst epileptic patients, when compared with a control population. An estimate of the odds ratio may suggest an increased risk [95% CI (confidence interval) 1.043-4.734] of up to 5-fold in epileptic patients carrying this mutation. This provides further evidence for a potential link between the debrisoquine hydroxylase gene polymorphism and CNS disorder and therefore warrants further study.

Acetylation↗
PubMed1993

[Anticonvulsant bromide therapy once and today].

During the past two decades, Bromides have undergone a renaissance as anticonvulsants. In this paper 6 indications for a modern bromide therapy are proposed. Guidelines referring to the concrete application of the drug, proposals concerning the dosage and any side effects are described. The present paper recalls the history of the first objectively effective treatment for confirmed epileptic syndromes and/or problems in the course of standard therapy (provocation of seizures, side effects, problematic interactions).

Anticonvulsants↗
PubMed1993

[Wasted years--politics and the promille limit].

Already as early as 1955 the German Federal Board of Health pointed out that the legal treatment of drunken drivers according to traffic (criminal) law regulations was not in accord with the proven effects of alcohol upon the human system and traffic safety. The Board of Health therefore recommended a revision of the regulation. The acceptable percent of alcohol in the blood of a driver should not exceed 0.08% while the said person is operating a motorized vehicle. Further, if a driver is found to be over the limit, he will be punished by law. This author has shown the extent to which policymakers have gone in attempting to pass laws which concur with recommendations resulting from scientific/medical research. Regarding this issue, it is especially disturbing that little attempt has been made to assimilate East German law into West German law.

Alcohol Drinking↗